Stay updated with breaking news from Third Bancorp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wedbush restated their neutral rating on shares of Toll Brothers (NYSE:TOL – Free Report) in a research note released on Wednesday morning, Marketbeat Ratings reports. Wedbush currently has a $105.00 price objective on the construction company’s stock. Wedbush also issued estimates for Toll Brothers’ Q3 2024 earnings at $3.29 EPS, Q4 2024 earnings at $4.27 […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target lowered by HC Wainwright from $94.00 to $90.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. CYTK has been the topic of several other research reports. JMP Securities reduced their price target on shares […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target lowered by Bank of America from $70.00 to $60.00 in a research report report published on Thursday, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the company. Barclays decreased their target […]
Cambridge Investment Research Advisors Inc. lessened its position in shares of JPMorgan BetaBuilders U.S. Aggregate Bond ETF (NYSEARCA:BBAG – Free Report) by 30.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 313,181 shares of the company’s stock after selling 139,495 shares […]
US Bancorp DE lowered its holdings in shares of Leggett & Platt, Incorporated (NYSE:LEG – Free Report) by 6.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 688,053 shares of the company’s stock after selling 43,668 shares during the period. […]